Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters

Contraception

Volumn 67, Issue 5, 2003, Pages 361-366

  Wiegratz, I ^a   Kutschera, E ^a   Lee, J H ^a   Moore, C ^b   Mellinger, U ^b   Winkler, U H ^c   Kuhl, H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Dept of Obstetrics and Gynecology ^*  (Germany)

Author keywords

Aldosterone; Angiotensin II; Cortisol; Dienogest; Endothelin 1; Estradiol valerate; Ethinylestradiol; Oral contraceptives; Thyroid hormones

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ENDOTHELIN 1; ESTRADIOL VALERATE; ETHINYLESTRADIOL; HYDROCORTISONE; LEIOS; LEVONORGESTREL; LIOTHYRONINE; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADRENAL FUNCTION; ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LOW DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; THYROID FUNCTION;

EID: 0038397351     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(03)00006-4     Document Type: Article

References (30)

1. Weeke J., Hansen A.P. Serum TSH and serum T3 levels during normal menstrual cycles and during cycles on oral contraceptives. Acta Endocrinol. 79:1975;431-438.
2. Kuhl H., Gahn G., Romberg G., Althoff P.H., Taubert H.D. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters II. Effects upon thyroid function, gastrin, STH and glucose tolerance . Contraception. 32:1985;97-107.
3. Scott E.M., McGarrigle H.H., Lachelin G.C.L. The increase in plasma and saliva cortisol levels in pregnancy is not due to the increase in corticosteroid binding globulin levels. J Clin Endocrinol Metab. 71:1990;639-644.
4. Kuhl H., Jung-Hoffmann C., Weber J., Boehm B.O. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception. 47:1993;55-68.
5. Wiegratz I, Jung-Hoffmann, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995;51:341-6.
6. Mandel F.P., Geola F.L., Lu J.K.H., et al. Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol. 59:1982;673-679.
7. Fern M., Rose D.P., Fern E.B. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol. 51:1978;541-544.
8. Beckerhoff R., Armbruster H., Vetter W., Luetscher J.A., Siegenthaler W. Plasma aldosterone during oral contraceptive therapy. Lancet. 1:1973;1218-1220.
9. Oelkers W.K.H. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 61:1996;166-171.
10. Skouby S.O. Laboratory and clinical assessment of a new progestational compound, desogestrel. Acta Obstet Gynecol Scand. 111:(Suppl):1982;7-11.
11. Vermeulen A., Thiery M. Metabolic effects of the triphasic oral contraceptive Trigynon. Contraception. 26:1982;505-513.
12. Penttilä I.M., Makkonen M., Castren O. Thyroid function during treatment with a new oral contraceptive combination containing desogestrel. Eur J Obstet Gynecol Reprod Biol. 16:1983;269-274.
13. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum binding globulins. Contraception 2003;67:25-32.
14. Ain K.B., Mori Y., Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation a mechanism for estrogen-induced elevation of serum TBG concentration . J Clin Endocrinol Metab. 65:1987;689-696.
15. Marqusee E., Braverman L.E., Lawrence J.E., Carroll J.S., Seely E.W. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab. 85:2000;4407-4410.
16. Kivelä A., Ruuskanen M., Agren U., Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care. 6:2001;71-77.
17. Jung-Hoffmann C., Fitzner M., Kuhl H. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel pharmacokinetics and pharmacodynamic parameters . Horm Res. 36:1991;238-246.
18. Marks L.J., Benjamin G., Duncan F.J., O'Sullivan J.V.I. Comparative effects of ethinyl estradiol, 17-ethyl-19-nortestosterone and methyltestosterone on the plasma clearance of infused cortisol. J Clin Endocrinol Metab. 21:1961;826-832.
19. Aden U., Jung-Hoffmann C., Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception. 58:1998;75-81.
20. Oelkers W., Blümel A., Schöneshöfer M., Schwartz U., Hammerstein J. Effects of ethinylestradiol on the renin-angiotensin-aldosterone system and on transcortin in women and men. J Clin Endocrinol Metab. 43:1976;1036-1040.
21. Cain M.D., Walters W.A., Catt K.J. Effects of oral contraceptive therapy on the renin-angiotensin system. J Clin Endocrinol Metab. 33:1971;671-676.
22. Oelkers W., Helmerhorst F.M., Wuttke W., Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol. 14:2000;204-213.
23. Ai-Feng Y., Shu-Xi W., Jin-Ling L., et al. Metabolic changes in women using a long-acting monthly oral contraceptive and return of ovulation on discontinuation. Contraception. 37:1988;517-528.
24. Crane M.G., Harris J.J., Windsor W. Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med. 74:1971;13-21.
25. Katz F.H., Beck P. Plasma renin activity, renin substrate and aldosterone during treatment with various oral contraceptives. J Clin Endocrinol Metab. 39:1974;1001-1004.
26. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 80:1995;1816-1821.
27. Bowyer L., Brown M.A., Jones M. Vascular reactivity in men and women of reproductive age. Am J Obstet Gynecol. 185:2001;88-96.
28. Merki-Feld G., Rosselli M., Raghvenda K.D., Jäger A.W., Keller P.J. Long-term effects of combined oral contraceptives on markers of endothelial functions and lipids in healthy premenopausal women. Contraception. 65:2002;231-236.
29. Wilcox J.G., Hatch I.E., Gentzschein E., Stanczyk F.Z., Lobo R.A. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril. 67:1997;273-277.
30. Ylikorkala O., Orpana A., Puolakka J., Pyörälä T., Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 80:1995;3384-3387.